PUMA BIOTECHNOLOGY, INC.

PUMA Biotechnology, Inc.

Biotechnology • Healthcare • Los Angeles, CA, United States • PBYI (NMS)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving Average - Here's What Happened - MarketBeat
MarketBeat • Dec 31
If EPS Growth Is Important To You, Puma Biotechnology (NASDAQ:PBYI) Presents An Opportunity - Yahoo Finance
Yahoo Finance • Dec 21
Puma Biotechnology: Step By Step In Making A Transition (NASDAQ:PBYI) - Seeking Alpha
Seeking Alpha • Nov 10
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? - Nasdaq
Nasdaq • Aug 12
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
simplywall.st • Nov 7

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has PUMA BIOTECHNOLOGY, INC. had layoffs?
No layoff events have been recorded for PUMA BIOTECHNOLOGY, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does PUMA BIOTECHNOLOGY, INC. have?
PUMA BIOTECHNOLOGY, INC. has approximately 172 employees.
What industry is PUMA BIOTECHNOLOGY, INC. in?
PUMA BIOTECHNOLOGY, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is PUMA BIOTECHNOLOGY, INC. a publicly traded company?
Yes, PUMA BIOTECHNOLOGY, INC. is publicly traded under the ticker symbol PBYI on the NMS. The company has a market capitalization of approximately $0.30 billion.
Where is PUMA BIOTECHNOLOGY, INC. headquartered?
PUMA BIOTECHNOLOGY, INC. is headquartered in Los Angeles, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.